Drug Profile
Atorvastatin/metformin - Daewoong Pharmaceutical
Alternative Names: Metformin/atorvastatinLatest Information Update: 22 Feb 2022
Price :
$50
*
At a glance
- Originator Daewoong Pharmaceutical
- Class Antihyperglycaemics; Antihyperlipidaemics; Biguanides; Fatty acids; Heptanoic acids; Pyrroles; Small molecules
- Mechanism of Action AMP activated protein kinase stimulants; Gluconeogenesis inhibitors; HMG-CoA reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Dyslipidaemias; Type 2 diabetes mellitus
Most Recent Events
- 22 Feb 2022 Discontinued - Phase-III for Dyslipidaemias in South Korea (PO) (Daewoong Pharmaceutical pipeline, February 2022)
- 22 Feb 2022 Discontinued - Phase-III for Type 2 diabetes mellitus in South Korea (PO) (Daewoong Pharmaceutical pipeline, February 2022)
- 27 Feb 2017 Daewoong Pharmaceutical completes a phase-III trial in Dyslipidaemias and Type-2 diabetes mellitus in South Korea (PO) (NCT02947620)